Literature DB >> 16234359

Epstein-Barr virus: the impact of scientific advances on clinical practice.

Hilary Williams1, Dorothy H Crawford.   

Abstract

Epstein-Barr virus (EBV) is a tumorigenic herpes virus that infects and persists in B lymphocytes in the majority of humans, generally without causing disease. However, in a few individuals the virus is associated with significant pathology, particularly benign and malignant lymphoproliferations. Recently acquired knowledge on the mechanisms of EBV persistence, immune control of primary and persistent infection, and disease pathogenesis is now being translated into the clinic with novel methods of diagnosis, prevention and treatment contributing to improved patient care. This review concentrates on these recent advances in the field of hematology/oncology.

Entities:  

Mesh:

Year:  2005        PMID: 16234359     DOI: 10.1182/blood-2005-07-2702

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines.

Authors:  Zachary L Pratt; Malika Kuzembayeva; Srikumar Sengupta; Bill Sugden
Journal:  Virology       Date:  2009-02-12       Impact factor: 3.616

3.  Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.

Authors:  Norman I Maldonado; Fernando Cabanillas; Elaine S Jaffe; Mark Raffeld; Luis Lozada
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

4.  Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1.

Authors:  Gaoxin Li; Ling Ding; Xiaojing Ma; Qiliang Cai; Tianlei Ying; Fang Wei
Journal:  Virol Sin       Date:  2019-04-04       Impact factor: 4.327

5.  Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression.

Authors:  Zhenyang Gu; Bo Cai; Lei Yuan; Honghua Li; Wenrong Huang; Yu Jing; Haiyan Zhu; Yu Zhao; Jian Bo; Quanshun Wang; Xiaoping Han; Li Yu; Chunji Gao
Journal:  Int J Clin Exp Med       Date:  2014-07-15

6.  Prevalence and Clinical Characteristics of Primary Epstein-Barr Virus Infection Among Children Presented with Cervical Lymphadenopathy.

Authors:  Jalal Ali Bilal
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 7.  Immunotherapy against cancer-related viruses.

Authors:  Haruko Tashiro; Malcolm K Brenner
Journal:  Cell Res       Date:  2016-12-23       Impact factor: 25.617

Review 8.  Systemic Epstein-Barr virus-positive T/natural killer-cell lymphoproliferative disorder: a case report and review of literature.

Authors:  Xia Tan; Xianling Liu; Chunhong Hu; Fuyou Liu; Fang Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 9.  Epstein-Barr virus and multiple sclerosis.

Authors:  Jan D Lünemann; Christian Münz
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

10.  Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant.

Authors:  Luciana Cristina Fagundes Gequelin; Irina N Riediger; Sueli M Nakatani; Alexander W Biondo; Carmem M Bonfim
Journal:  Rev Bras Hematol Hemoter       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.